Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 164

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma

Open access
Oussalah, Abderrahim, Rischer, Susann, Bensenane, Mouni, Conroy, Guillaume, Filhine-Tresarrieu, Pierre, Debard, Renée, Forest-Tramoy, Denise, Josse, Thomas, Reinicke, Dana, Garcia, Matthieu, Luc, Amandine, Baumann, Cédric, Ayav, Ahmet, Laurent, Valérie, Hollenbach, Marcus, Ripoll, Cristina, Guéant-Rodriguez, Rosa-Maria, Namour, Fares, Zipprich, Alexander, Fleischhacker, Michael, Bronowicki, Jean-Pierre, Guéant, Jean-Louis · 2018 · eBioMedicine

Abstract

Background Patients with cirrhosis are at high risk of hepatocellular carcinoma (HCC). The SEPT9 gene is a key regulator of cell division and tumor suppressor whose hypermethylation is associated with liver carcinogenesis. The primary aim of this study was to evaluate the diagnostic accuracy of a PCR-based assay for the analysis of SEPT9 promoter methylation in circulating cell-free DNA (m SEPT9 ) for diagnosing HCC among cirrhotic patients. Methods We report two phase II biomarker studies that included cirrhotic patients with or without HCC from France (initial study) and Germany (replication study). All patients received clinical and biological evaluations, and liver imaging according to current recommendations. The primary outcome was defined as the presence of HCC according to guidelines from the American Association for the Study of Liver Diseases. The diagnosis of HCC was confirmed by abdominal contrast-enhanced computed tomography scan and systematically discussed in a multidisciplinary consultation meeting. HCC-free cirrhotic patients were recruited if the screening abdominal ultrasound showed no evidence of HCC at the time of blood sampling for the m SEPT9 test and on the next visit six months later. The adjudicating physicians were blinded to patient results associated with the m SEPT9 test. Findings We included 289 patients with cirrhosis (initial: 186; replication: 103), among whom 98 had HCC (initial: 51; replication: 47). The m SEPT9 test exhibited high diagnostic accuracy for HCC diagnosis, with an area under the receiver operating characteristic curve (AUROC) of 0.944 (0.900–0.970, p<0.0001) in the initial study (replication: 0.930 [0.862–0.971, p<0.0001]; meta-analysis: AUROC=0.940 [0.910–0.970, p<0.0001], no heterogeneity: I 2 =0%, p=0.67; and no publication bias). In multivariate logistic regression analysis, the number of positive m SEPT9 triplicates was the only independent variable significantly associated with HCC diagnosis (initial: OR=6.30, for each m SEPT9 positive triplicate [2.92–13.61, p<0.0001]; replication: OR=6.07 [3.25–11.35, p<0.0001]; meta-analysis: OR=6.15 [2.93–9.38, p<0.0001], no heterogeneity: I 2 =0%, p=0.95; no publication bias). AUROC associated with the discrimination of the logistic regression models in initial and validation studies were 0.969 (0.930–0.989) and 0.942 (0.878–0.978), respectively, with a pooled AUROC of 0.962 ([0.937–0.987, p<0.0001], no heterogeneity: I 2 =0%, p=0.36; and no publication bias). Interpretation Among patients with cirrhosis, the m SEPT9 test constitutes a promising circulating epigenetic biomarker for HCC diagnosis at the individual patient level. Future prospective studies should assess the m SEPT9 test in the screening algorithm for cirrhotic patients to improve risk prediction and personalized therapeutic management of HCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ebiom.2018.03.029

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 164

Metadata

Authors
Oussalah, A., Rischer, S., Bensenane, M., Conroy, G., Filhine-Tresarrieu, P., Debard, R., Forest-Tramoy, D., Josse, T., Reinicke, D., Garcia, M., Luc, A., Baumann, C., Ayav, A., Laurent, V., Hollenbach, M., Ripoll, C., Guéant-Rodriguez, R.-M., Namour, F., Zipprich, A., Fleischhacker, M., Bronowicki, J.-P., & Guéant, J.-L.
Venue
eBioMedicine
Publisher
Elsevier BV
Published
2018-04
Volume
30
Pages
138-147
ISSN
2352-3964 (ISSN-L)
OpenAlex
W2794450296
Cited by
164
References
4
FWCI
8.53
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1016/j.ebiom.2018.03.029
The paper
Oussalah, A., Rischer, S., Bensenane, M., Conroy, G., Filhine-Tresarrieu, P., Debard, R., Forest-Tramoy, D., Josse, T., Reinicke, D., Garcia, M., Luc, A., Baumann, C., Ayav, A., Laurent, V., Hollenbach, M., Ripoll, C., Guéant-Rodriguez, R.-M., Namour, F., Zipprich, A., . . . Guéant, J.-L. (2018). Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. eBioMedicine. https://doi.org/10.1016/j.ebiom.2018.03.029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.